Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
May 26 2015 - 2:37PM
Edgar (US Regulatory)
Free Writing Prospectus
Filed Pursuant to Rule 433
Registration Statement No. 333-186979
Dated May 26, 2015
Eli Lilly and Company
Pricing Term Sheet
1.000% Notes due 2022
1.625% Notes due 2026
2.125% Notes due 2030
|
| | | |
Issuer: | Eli Lilly and Company |
| | | |
Principal Amount: | €600,000,000 | €750,000,000 | €750,000,000 |
| | | |
Maturity Date: | June 2, 2022 | June 2, 2026 | June 3, 2030 |
| | | |
Coupon: | 1.000% per year | 1.625% per year | 2.125% per year |
| | | |
Public Offering Price: | 99.617% of principal amount | 99.541% of principal amount | 98.473% of principal amount |
| | | |
Yield to Maturity: | 1.057% | 1.671% | 2.246% |
| | | |
Benchmark Bund: | DBR 2.000% due January 4, 2022 | DBR 0.500% due February 15, 2025 | DBR 4.750% due July 4, 2028 |
| | | |
Spread to Benchmark Bund: | +86.3 bps | +112.7 bps | +149.3 bps |
| | | |
Benchmark Bund Yield / Price: | 0.194% / 111.84 | 0.544% / 99.58 | 0.753% / 149.68 |
| | | |
Spread to Mid Swaps: | +45 bps | +70 bps | +107 bps |
| | | |
Mid Swaps Yield: | 0.607% | 0.971% | 1.176% |
| | | |
Interest Payment Dates: | Annually on June 2, commencing June 2, 2016 | Annually on June 2, commencing June 2, 2016 | Annually on June 3, commencing June 3, 2016 |
| | | |
Redemption Provisions: | | | |
Make-whole call: | Prior to March 2, 2022, make whole plus 15 bps, plus accrued and unpaid interest, if any | Prior to March 2, 2026, make whole plus 20 bps, plus accrued and unpaid interest, if any | Prior to March 3, 2030, make whole plus 25 bps, plus accrued and unpaid interest, if any |
Par call: | On or after March 2, 2022, at 100%, plus accrued and unpaid interest, if any | On or after March 2, 2026, at 100%, plus accrued and unpaid interest, if any | On or after March 3, 2030, at 100%, plus accrued and unpaid interest, if any |
| | | |
|
| | | |
Underwriting Discounts: | 0.400% | 0.475% | 0.550% |
| | | |
CUSIP / ISIN / Common Code: | 532457 BL1 / XS1240750767 / 124075076 | 532457 BM9 / XS1240751062 / 124075106 | 532457 BN7 / XS1240751229 / 124075122 |
| | | |
Trade Date: | May 26, 2015 |
| | | |
Settlement Date: | June 2, 2015 (T+5) |
| | | |
Expected Ratings*: | Moody’s: A2 (Stable); Standard & Poor’s: AA- (Stable) |
| | |
Denominations: | €100,000 and integral multiples of €1,000 in excess thereof |
| | | |
Day Count: | Actual / Actual (ICMA) |
| | |
Offering Format: | SEC Registered |
| | |
Listing: | Application will be made to list the notes on the New York Stock Exchange |
| | |
Joint Book-Running Managers: | Credit Suisse Securities (Europe) Limited, Deutsche Bank AG, London Branch, J.P. Morgan Securities plc, Morgan Stanley & Co. International plc and UBS Limited |
| | | |
Co-Managers: | Barclays Bank PLC and Drexel Hamilton, LLC | |
*Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Credit Suisse Securities (Europe) Limited toll-free at 1-800-221-1037, Deutsche Bank AG, London Branch toll-free at 1-800-503-4611 and J.P. Morgan Securities plc collect at +44-207-134-2468.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024